Please Scroll Down to See Forums Below
Vitamin C post
- Thread starter celica
- Start date
galaxy said:
At the ripe old age of 93!
Linus Carl Pauling was born in Portland, Oregon, on 28th February, 1901, the son of a druggist, Herman Henry William Pauling, who, though born in Missouri, was of German descent, and his wife, Lucy Isabelle Darling, born in Oregon of English-Scottish ancestry.
Linus attended the public elementary and high schools in the town of Condon and the city of Portland, Oregon, and entered the Oregon State College in 1917, receiving the degree of B.Sc. in chemical engineering in 1922. During the years 1919-1920 he served as a full-time teacher of quantitative analysis in the State College, after which he was appointed a Teaching Fellow in Chemistry in the California Institute of Technology and was a graduate student there from 1922 to 1925, working under Professor Roscoe G. Dickinson and Richard C. Tolman. In 1925 he was awarded the Ph.D. (summa cum laude) in chemistry, with minors in physics and mathematics.
Since 1919 his interest lay in the field of molecular structure and the nature of the chemical bond, inspired by papers by Irving Langmuir on the application of the Lewis theory of the sharing of pairs of electrons between atoms to many substances. In 1921 he suggested, and attempted to carry out, an experiment on the orientation of iron atoms by a magnetic field, through the electrolytic deposition of a layer of iron in a strong magnetic field and the determination of the orientation of the iron crystallises by polishing and etching the deposit, and microscopic examination of the etch figures. With Professor Dickinson, he began in 1922 the experimental determination of the structures of some crystals, and also started theoretical work on the nature of the chemical bond.
Since his appointment to the Staff of California Institute of Technology, Professor Pauling was elected Research Associate in 1925; National Research Fellow in Chemistry, 1925-1926; Fellow of the John Simon Guggenheim Memorial Foundation, 1926-1927 (through this last he worked in European Universities with Sommerfeld, Schrödinger, and Bohr); Assistant Professor of Chemistry, 1927-1929; Associate Professor, 1929-1931; Professor, 1931, when he was the first recipient of the American Chemical Society Award in Pure Chemistry - the Langmuir Prize - and Chairman of the Division of Chemistry and Chemical Engineering, and Director of the Gates and Crellin laboratories of Chemistry, 1936-1958. In 1963, he was awarded the Nobel Peace Prize.
Pauling is a member of numerous professional societies in the U.S.A. as well as in many European countries, India, Japan and Chile. Awards, medals, and honorary degrees were showered upon him in America and Europe, and in addition he was elected Rationalist of the Year for 1960 and Humanist of the Year for 1961. Several books have come from his pen, ranging from his most famous one The Nature of the Chemical Bond, and the Structure of Molecules and Crystals (1939, 1949, 1960) via General Chemistry (1947, 1953), which was translated into nine languages, to No More War! (1958, 1959,1962).
The subjects of the papers he published reflect his great scientific versatility: about 350 publications in the fields of experimental determination of the structure of crystals by the diffraction of X-rays and the interpretation of these structures in terms of the radii and other properties of atoms; the application of quantum mechanics to physical and chemical problems, including dielectric constants, X-ray doublets, momentum distribution of electrons in atoms, rotational motion of molecules in crystals, Van der Waals forces, etc.; the structure of metals and intermetallic compounds, the theory of ferromagnetism; the nature of the chemical bond, including the resonance phenomenon in chemistry; the experimental determination of the structure of gas molecules by the diffraction of electrons; the structure of proteins; the structure of antibodies and the nature of serological reactions; the structure and properties of hemoglobin and related substances; abnormal hemoglobin molecules in relation to the hereditary hemolytic anemias; the molecular theory of general anesthesia; an instrument for determining the partial pressure of oxygen in a gas; and other subjects.
Pauling married Ava Helen Miller of Beaver Creek, Oregon, in 1923. She is of English-Scottish and German descent. They have four children, Linus (Carl) Jr. (1925), Peter Jeffress (1931), Linda Helen (1932) and Edward Crellin (1937), and thirteen grandchildren.
From Nobel Lectures, Chemistry 1942-1962, Elsevier Publishing Company, Amsterdam, 1964
This autobiography/biography was written at the time of the award and later published in the book series Les Prix Nobel/Nobel Lectures. The information is sometimes updated with an addendum submitted by the Laureate. To cite this document, always state the source as shown above.
Linus Pauling died on August 19, 1994.
Triple J
New member
Pubmed, try it some time. Search ascorbic acid cancer - lots more besides this
http://www.ncbi.nlm.nih.gov/entrez/..._uids=16567755&query_hl=1&itool=pubmed_docsum
Intravenously administered vitamin C as cancer therapy: three cases.
Padayatty SJ, Riordan HD, Hewitt SM, Katz A, Hoffer LJ, Levine M.
Molecular and Clinical Nutrition Section, Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Md 20892-1372, USA.
Early clinical studies showed that high-dose vitamin C, given by intravenous and oral routes, may improve symptoms and prolong life in patients with terminal cancer. Double-blind placebo-controlled studies of oral vitamin C therapy showed no benefit. Recent evidence shows that oral administration of the maximum tolerated dose of vitamin C (18 g/d) produces peak plasma concentrations of only 220 micromol/L, whereas intravenous administration of the same dose produces plasma concentrations about 25-fold higher. Larger doses (50-100 g) given intravenously may result in plasma concentrations of about 14,000 micromol/L. At concentrations above 1000 micromol/L, vitamin C is toxic to some cancer cells but not to normal cells in vitro. We found 3 well-documented cases of advanced cancers, confirmed by histopathologic review, where patients had unexpectedly long survival times after receiving high-dose intravenous vitamin C therapy. We examined clinical details of each case in accordance with National Cancer Institute (NCI) Best Case Series guidelines. Tumour pathology was verified by pathologists at the NCI who were unaware of diagnosis or treatment. In light of recent clinical pharmacokinetic findings and in vitro evidence of anti-tumour mechanisms, these case reports indicate that the role of high-dose intravenous vitamin C therapy in cancer treatment should be reassessed.
Publication Types:
* Case Reports
http://www.ncbi.nlm.nih.gov/entrez/..._uids=16567755&query_hl=1&itool=pubmed_docsum
Intravenously administered vitamin C as cancer therapy: three cases.
Padayatty SJ, Riordan HD, Hewitt SM, Katz A, Hoffer LJ, Levine M.
Molecular and Clinical Nutrition Section, Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Md 20892-1372, USA.
Early clinical studies showed that high-dose vitamin C, given by intravenous and oral routes, may improve symptoms and prolong life in patients with terminal cancer. Double-blind placebo-controlled studies of oral vitamin C therapy showed no benefit. Recent evidence shows that oral administration of the maximum tolerated dose of vitamin C (18 g/d) produces peak plasma concentrations of only 220 micromol/L, whereas intravenous administration of the same dose produces plasma concentrations about 25-fold higher. Larger doses (50-100 g) given intravenously may result in plasma concentrations of about 14,000 micromol/L. At concentrations above 1000 micromol/L, vitamin C is toxic to some cancer cells but not to normal cells in vitro. We found 3 well-documented cases of advanced cancers, confirmed by histopathologic review, where patients had unexpectedly long survival times after receiving high-dose intravenous vitamin C therapy. We examined clinical details of each case in accordance with National Cancer Institute (NCI) Best Case Series guidelines. Tumour pathology was verified by pathologists at the NCI who were unaware of diagnosis or treatment. In light of recent clinical pharmacokinetic findings and in vitro evidence of anti-tumour mechanisms, these case reports indicate that the role of high-dose intravenous vitamin C therapy in cancer treatment should be reassessed.
Publication Types:
* Case Reports
Triple J
New member
http://www.ncbi.nlm.nih.gov/entrez/..._uids=16116933&query_hl=1&itool=pubmed_DocSum
Effects of high dose ascorbate administration on L-10 tumor growth in guinea pigs.
Casciari JJ, Riordan HD, Miranda-Massari JR, Gonzalez MJ.
Center for the Improvement of Human Functioning, Bio-communications Research Institute, 3100 N Hillside Avenue, Wichita, KS 67219, USA.
Sodium ascorbate is preferentially toxic to tumor cells at high concentrations. It has not been established, however, whether sufficient intra-tumor ascorbate concentrations are safely achievable in vivo. We administered sodium ascorbate subcutaneously or orally for eighteen days to Sewall-Wright strain-2 guinea pigs bearing intradermal L-10 hepatocarcinoma tumors. Tumor masses and intra-tumor ascorbate concentrations were determined at necropsy. L-10 cells formed tumors that metastasized to the lymph nodes, with tumor burdens reaching nearly 50 grams in untreated animals. Subcutaneous injections of ascorbate (500 mg/kg/day) inhibited tumor growth by as much as sixty-five percent, with oral supplementation reducing it by roughly fifty percent. Tumor growth correlated inversely with intra-tumor ascorbate concentration, the latter exceeding 2 mM in some cases. Ascorbate concentrations sufficient to kill tumor cells can be safely achieved in solid tumors in vivo, suggesting a possible role for high dose intravenous ascorbate in treating cancer.
Effects of high dose ascorbate administration on L-10 tumor growth in guinea pigs.
Casciari JJ, Riordan HD, Miranda-Massari JR, Gonzalez MJ.
Center for the Improvement of Human Functioning, Bio-communications Research Institute, 3100 N Hillside Avenue, Wichita, KS 67219, USA.
Sodium ascorbate is preferentially toxic to tumor cells at high concentrations. It has not been established, however, whether sufficient intra-tumor ascorbate concentrations are safely achievable in vivo. We administered sodium ascorbate subcutaneously or orally for eighteen days to Sewall-Wright strain-2 guinea pigs bearing intradermal L-10 hepatocarcinoma tumors. Tumor masses and intra-tumor ascorbate concentrations were determined at necropsy. L-10 cells formed tumors that metastasized to the lymph nodes, with tumor burdens reaching nearly 50 grams in untreated animals. Subcutaneous injections of ascorbate (500 mg/kg/day) inhibited tumor growth by as much as sixty-five percent, with oral supplementation reducing it by roughly fifty percent. Tumor growth correlated inversely with intra-tumor ascorbate concentration, the latter exceeding 2 mM in some cases. Ascorbate concentrations sufficient to kill tumor cells can be safely achieved in solid tumors in vivo, suggesting a possible role for high dose intravenous ascorbate in treating cancer.
Triple J
New member
my point is there are scientists who are actively researching this, so there are valid scientific arguments and evidence supporting ascorbic as being useful against cancer at least under certain conditions, and there are people who have benefited in their fights against cancer by using vitamin c. so do not dismiss this out-of-hand, do your own research
Ive been all over pubmed and you wont find anything about vit-c CURING cancers. All cancers are different, some overexpress isotopomerase, some underexpress MHC I, over express various receptors. Sure in some cases, there may be a mutation that can make some cancers suceptable to high ascorbic acid, FAS blockers, hormone blockers....this is nothing new....but you have to test the biopsy individually to see whats going on with those cells, something not done all the time (hopefully one day it will be done with everyone to make personal therapies and greatly increase effectiveness). To say blanketly that vit-c cures cancer is whack, iven in the above posts, it says PROLONG survival, not cure......you can get that with Gemzar or Cisplatin too (much more toxic though).
Im all for anything that can help, throw the book at the tumor, but each case is different.
Im all for anything that can help, throw the book at the tumor, but each case is different.
massatronic
New member
krishna said:
I'm the same, increased dose doesnt seem to help stave off colds/flu, sometimes seems to do the opposite. Dosage conservative though, next time I'll hit it early with 5-10g and see what happens.
NFG123 said:
I not be up to the minute but as far as I know there are is clear evidence that it doesn't. What is usually as important to the average cold sufferer is the lessening on symtoms due to the virus. Here is where a large degree of anecdotal evidence is enough for most of us to want to give it consideration.
I also think it's safe to say that Pauling, though of course the most famous endorser of Vit. C shouldn't be considered the one absolute authority. There's still alot we need to know and I feel some of his later writings may have been tinted by his personal experience. It doesn't lessen his contribution and there are many other respected favorable opinions as well.
Similar threads
